Clinical Trials Directory

Trials / Conditions / Advanced NSCLC

Advanced NSCLC

22 registered clinical trials studyying Advanced NSCLC — 10 currently recruiting.

StatusTrialSponsorPhase
RecruitingEvaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Ch
NCT06924606
Shanghai Junshi Bioscience Co., Ltd.Phase 2
Not Yet RecruitingA Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NCT05859217
Jun Zhang, MD, PhDPhase 2
RecruitingNeoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-l
NCT06752044
The First Affiliated Hospital of Nanchang UniversityN/A
RecruitingNeoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line
NCT06752057
The First Affiliated Hospital of Nanchang UniversityN/A
Not Yet RecruitingA Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-n
NCT06356675
The First Affiliated Hospital, Guangzhou University of Traditional Chinese MedicinePhase 4
RecruitingNeoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-
NCT06751901
The First Affiliated Hospital of Nanchang UniversityPhase 2
RecruitingNeoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line
NCT06751849
The First Affiliated Hospital of Nanchang UniversityPhase 2
RecruitingA Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557
Huabo Biopharm Co., Ltd.Phase 1 / Phase 2
UnknownNingetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
NCT04992858
Sunshine Lake Pharma Co., Ltd.Phase 2
RecruitingCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Mirati Therapeutics Inc.Phase 2
CompletedReal-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Ther
NCT05219162
AstraZenecaPhase 4
TerminatedA Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
NCT05106335
Jiangsu HengRui Medicine Co., Ltd.Phase 3
TerminatedStudy of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transit
NCT04982224
Regeneron PharmaceuticalsPhase 1
UnknownClinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC
NCT04229121
Shanghai Pulmonary Hospital, Shanghai, China—
Active Not RecruitingNivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
NCT04043195
Hatim HusainPhase 1 / Phase 2
CompletedNivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
NCT03215810
H. Lee Moffitt Cancer Center and Research InstitutePhase 1
CompletedPlasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advan
NCT03074175
Xinqiao Hospital of ChongqingN/A
TerminatedAST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
NCT03127449
Allist Pharmaceuticals, Inc.N/A
UnknownStudy of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
NCT03062800
Qilu Hospital of Shandong UniversityPhase 2
RecruitingT Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
NCT02133196
National Cancer Institute (NCI)Phase 2
CompletedPOSITIVE - Study (Part III) Heidelberg
NCT02055508
German Cancer Research CenterN/A
UnknownSecond-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NS
NCT00813332
Simcere Pharmaceutical Co., LtdPhase 4